This activity provides a review of data from the Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination in patients with blood cancer and audience Q&A.
This activity will cover the latest advancements in biology and treatments for acute myeloid leukemia, aggressive lymphoma, and myeloma. The development and practical applications for CAR T-cell therapy in blood cancers is presented. A review of data from the Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination and antibody response in patients with blood cancer provides a glimpse of unmet needs in this vulnerable patient population.
Upon completion of this activity, participants should be better able to:
Executive Research Director
The Leukemia & Lymphoma Society
Rye Brook, NY
Kraft Family Professor of Medicine
Harvard Medical School
Program Director, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, MA
Chief Scientific Officer
The Leukemia & Lymphoma Society
Rye Brook, NY
Richard W. Vague Professor, Immunotherapy
Director, Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy
University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA
Professor, Medicine
Director, Clinical and Translational Leukemia Program
Weill Medical College of Cornell University
Division of Hematology and Oncology
New York-Presbyterian Hospital
New York, NY
Chief, Lymphoid Malignancies Branch
Director, Center for Cancer Genomics
National Cancer Institute
Bethesda, MD
Featured RMEI CE Activities – Earn CE Credit(s)
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
